Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

A decision is expected in the fourth quarter of 2025.

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...